Photo taken from Vivek Subbiah/LinkedIn
Aug 1, 2023, 06:57
🚨It’s monday & we have another FDA approval – Vivek Subbiah
🚨It’s monday & we have another FDA approval
👉FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
👉Read our paper just published in Cell Press Journal Trends in Cancer on “Tumor-agnostic drug development in dMMR/MSI-H solid tumors”.
Link to paper: Click here
👉Link to FDA approval in tumor specific endometrial context: Click here
Source: Vivek Subbiah / Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54